GlassScriptPhysician profile
Kolt Michael Nezat
NPI 1558834150
$5,221.15
in general payments reported to CMS, 2019-2025
35 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $953 · 2022: $1,021 · 2023: $1,023 · 2024: $990 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,999 · Consulting Fee: $150 · Education: $97.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,998.67 |
| Consulting Fee | $150.00 |
| Education | $97.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,073.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $776.40 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $417.49 | 2022-2025 | Sunosi, Auvelity |
| Jazz Pharmaceuticals INC. | $346.22 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $284.85 | 2021-2024 | Trintellix |
| Esperion Therapeutics, INC. | $262.25 | 2021-2024 | Nexletol |
| Lilly USA, LLC | $233.92 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $233.90 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $224.87 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Harmony Biosciences LLC | $200.06 | 2022-2025 | Wakix |
| Sanofi-Aventis U.S. LLC | $113.20 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $113.17 | 2024-2025 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $108.35 | 2021-2025 | |
| Astellas Pharma US INC | $107.59 | 2023-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.91 | 2022-2025 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.80 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.88 | 2022 | |
| Phathom Pharmaceuticals, INC. | $49.92 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $48.42 | 2023-2025 | Cologuard Collection Kit |
| Avadel Cns Pharmaceuticals, LLC | $44.84 | 2025 | Lumryz |
| Adlon Therapeutics L.P. | $44.45 | 2021 | |
| Paratek Pharmaceuticals, INC. | $38.54 | 2021 | |
| Idorsia Pharmaceuticals US INC | $36.11 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.24 | 2021-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $26.96 | 2021 | |
| Currax Pharmaceuticals LLC | $26.76 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.26 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.75 | 2021 | |
| Abbott Laboratories | $17.56 | 2024 | Eterna |
| Lundbeck LLC | $17.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.67 | 2021 | |
| Eisai INC. | $15.64 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2023 | Jardiance |
| Amgen INC. | $13.91 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kolt Nezat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.